pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
183
stories
21d
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
25d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
25d
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
27d
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
27d
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
27d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 5, 26
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
endpoints
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
Aug 31, 26
Lilly adds to immune drug pipeline with $2.9B Merida buyout
biopharma dive
Aug 31, 26
Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug
endpoints
Aug 31, 26
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
endpoints
Aug 31, 26
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
biospace
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 28, 26
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
biospace
Aug 28, 26
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
biospace
Aug 28, 26
CAR T for autoimmune disease benefits from oncology’s lessons—and will deliver its own
biospace
Aug 27, 26
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
fda press
Aug 27, 26
Generate Bio drops as data accidentally leaked ahead of European conference
biospace
Aug 27, 26
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
Aug 27, 26
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
biospace
Aug 27, 26
STAT+: The mystery of Moderna’s magic algorithm
stat
Aug 27, 26
CAR Ts will only treat autoimmune diseases if we can scale delivery
biospace
Aug 26, 26
China in Global Clinical Development: Why Early Inclusion Matters
fiercebiotech
Aug 26, 26
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
biopharma dive
Aug 26, 26
JATT mastermind launches latest biotech-focused SPAC via $60M IPO
fiercebiotech
← prev
page 3 of 7
next →
